ArticleThe American journal of pathology2007
Genetic mapping in mice identifies DMBT1 as a candidate modifier of mammary tumors and breast cancer risk.
Article in The American journal of pathology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- Genetic modifiers of p53: opportunities for breast cancer therapies.Oncotarget · 2023Article
- Reg3A (regenerating family member 3 alpha) acts as a tumor suppressor by targeting DMBT1 (deleted in malignant brain tumors 1) in gastric cancer.Bioengineered · 2021Article
- Article
- Squamous cell carcinoma subverts adjacent histologically normal epithelium to promote lateral invasion.The Journal of experimental medicine · 2021Article
- Prolactin synergizes with canonical Wnt signals to drive development of ER+ mammary tumors via activation of the Notch pathway.Cancer letters · 2021Article
- Vitamin D Metabolite Profile in Cholecalciferol- or Calcitriol-Supplemented Healthy and Mammary Gland Tumor-Bearing Mice.Nutrients · 2020Article
- Distinct Tumor Microenvironments Are a Defining Feature of Strain-Specific CRISPR/Cas9-Induced MPNSTs.Genes · 2020Article
- Survival Analysis of Multi-Omics Data Identifies Potential Prognostic Markers of Pancreatic Ductal Adenocarcinoma.Frontiers in genetics · 2019Article
- Mucosal fluid glycoprotein DMBT1 suppresses twitching motility and virulence of the opportunistic pathogen Pseudomonas aeruginosa.PLoS pathogens · 2017Article
- MMTV-cre;Ccn6 knockout mice develop tumors recapitulating human metaplastic breast carcinomas.Oncogene · 2017Article
- The Effects of Genetic Background of Mouse Models of Cancer: Friend or Foe?Cold Spring Harbor protocols · 2016Article
- MYC and PVT1 synergize to regulate RSPO1 levels in breast cancer.Cell cycle (Georgetown, Tex.) · 2016Article
- LINE-1 expression and retrotransposition in Barrett's esophagus and esophageal carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting.Journal of biomedical science · 2014Article
- Article
- Dmbt1 does not affect a Western style diet-induced liver damage in mice.Journal of clinical biochemistry and nutrition · 2013Article
- Identifying breast cancer risk loci by global differential allele-specific expression (DASE) analysis in mammary epithelial transcriptome.BMC genomics · 2012Article
- High DMBT1 concentrations in breast milk correlate with increased risk of infection in preterm and term neonates.BMC pediatrics · 2012Article
- Epistatic Control of Mammary Cancer Susceptibility in Mice may Depend on the Dietary Environment.Hereditary genetics : current research · 2012Article
- An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis.Cellular oncology (Dordrecht, Netherlands) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 3 countries.
Funding
Abstract
Low-penetrance breast cancer susceptibility alleles seem to play a significant role in breast cancer risk but are difficult to identify in human cohorts. A genetic screen of 176 N2 backcross progeny of two Trp53(+/-) strains, BALB/c and C57BL/6, which differ in their susceptibility to mammary tumors, identified a modifier of mammary tumor susceptibility in an approximately 25-Mb interval on mouse chromosome 7 (designated SuprMam1). Relative to heterozygotes, homozygosity for BALB/c alleles of SuprMam1 significantly decreased mammary tumor latency from 70.7 to 61.1 weeks and increased risk twofold (P = 0.002). Dmbt1 (deleted in malignant brain tumors 1) was identified as a candidate modifier gene within the SuprMam1 interval because it was differentially expressed in mammary tissues from BALB/c-Trp53(+/-) and C57BL/6-Trp53(+/-) mice. Dmbt1 mRNA and protein was reduced in mammary glands of the susceptible BALB/c mice. Immunohistochemical staining demonstrated that DMBT1 protein expression was also significantly reduced in normal breast tissue from women with breast cancer (staining score, 1.8; n = 46) compared with cancer-free controls (staining score, 3.9; n = 53; P < 0.0001). These experiments demonstrate the use of Trp53(+/-) mice as a sensitized background to screen for low-penetrance modifiers of cancer. The results identify a novel mammary tumor susceptibility locus in mice and support a role for DMBT1 in suppression of mammary tumors in both mice and women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.